Access and elimination: the future of DAAs in hepatitis C
How direct-acting antivirals are transforming treatment of hepatitis C.
How direct-acting antivirals are transforming treatment of hepatitis C.
Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
AbbVie aiming to steal market share from Gilead